Dr Gronchi speaks with ecancertv at ESMO 2016 about the responses of patients with advanced soft tissue sarcoma to adjuvant epirubicin plus ifosfamide compared to those receiving a tailored chemo regimen based on histology subgrouping
He reports significantly improved relapse-free survival and overall survival for patients receiving adjuvant chemo, thought notes the trial is a technical failure due to being powered for the histology-tailored sub types which did not show any benefit.
